Scarica l'app Stockscreener
97.98
6.22%
5.74
Dopo l'orario di chiusura:
97.98
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Incyte Corp Borsa (INCY) Ultime notizie
Incyte Corporation (INCY) Stock Price, News, Quote & History - Yahoo Finance
Incyte shares rise 6.2% amid renewed optimism around late-stage pipeline and recent partnership update - Quiver Quantitative
Incyte Corp. stock outperforms competitors on strong trading day - MSN
Incyte Stock Drops as Cancer Drug Data Hits: Wall Street Split Remains in Focus - Bez Kabli
Citizens maintains Incyte stock rating on pipeline progress By Investing.com - Investing.com Australia
Citizens maintains Incyte stock rating on pipeline progress - Investing.com
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
Stifel reiterates Incyte stock Buy rating on DLBCL data strength - Investing.com
H.C. Wainwright reiterates Incyte stock rating on lymphoma data - Investing.com
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL - BioSpace
Incyte (INCY) Reports Positive Phase 3 Trial Results for Tafasit - GuruFocus
Incyte (INCY) Reports Positive Phase 3 Trial Results for Tafasitamab - GuruFocus
Incyte (INCY) Monjuvi Shows Promise as First-Line Treatment for Lymphoma - GuruFocus
Incyte blood cancer drug combo reduces disease-progression risk but with high side-effect rate By Reuters - Investing.com
Incyte drug combo cuts risk of high-risk lymphoma worsening by 25% - Stock Titan
INCY News | INCYTE CORP (NASDAQ:INCY) - ChartMill
Incyte (INCY) accounting officer sells 2,051 common shares - Stock Titan
INCYTE (NASDAQ: INCY) director exercises 15,000 options and has shares withheld for taxes - Stock Titan
Why Is Incyte (INCY) Down 1.8% Since Last Earnings Report? - Yahoo Finance
Morgan Stanley sells INCY common shares (INCY) via Form 144 notice - Stock Titan
DIADEMA PARTNERS LP's Incyte Corp(INCY) Holding History - GuruFocus
Here's Why Incyte (INCY) is a Strong Momentum Stock - Yahoo Finance
Incyte to stream Goldman Sachs healthcare conference talk June 9 - Stock Titan
1INCY.MI Stock Price, Quote & Chart | INCYTE CORP (BIT:1INCY) - ChartMill
Incyte Sets Mid-Year Phase 3 Trial for CALR Antibody 989 as Pipeline Updates Roll Out - Barchart.com
INCYTE CORP (NASDAQ:INCY) Shows Rare Alignment of High Growth Momentum and Technical Breakout Setup - ChartMill
Continuum Advisory, LLC's Incyte Corp(INCY) Holding History - GuruFocus
INCY Initiates Coverage On Bernstein -- Rating Set to Market Per - GuruFocus
Here's Why Incyte (INCY) is a Strong Value Stock - Yahoo Finance
How Incyte’s AI-Powered R&D Partnerships At Incyte (INCY) Has Changed Its Investment Story - Yahoo Finance
Bernstein initiates Incyte stock coverage with concerns on growth By Investing.com - Investing.com South Africa
Incyte (INCY) Coverage Initiated with Caution by Bernstein - GuruFocus
Bernstein initiates Incyte stock coverage with concerns on growth - Investing.com UK
Bernstein SocGen Group Starts Incyte (INCY) at Market Perform - StreetInsider
Incyte (NASDAQ: INCY) director exercises options and sells 15K shares - Stock Titan
Why Incyte (INCY) is a Top Growth Stock for the Long-Term - Yahoo Finance
Incyte stock price target maintained at $135 by H.C. Wainwright - Investing.com
Incyte and Genesis expand molecular AI collaboration - The Pharma Letter
Incyte Corp stock (US45337C1027): focus on latest Jakafi data and pipeline outlook - AD HOC NEWS
Incyte expands AI drug discovery pact with $120M funding boost - MSN
How Incyte’s (INCY) Opzelura Data and Edison AI Deal Could Reframe Its Risk Profile - simplywall.st
Incyte Grants Equity Awards to New CFO Suketu Upadhyay - MyChesCo
Incyte (INCY) Expands AI Collaboration with Genesis Molecular - GuruFocus
Incyte (INCY) CMO granted 44,124 performance-based shares in Form 4/A - Stock Titan
Incyte (NASDAQ: INCY) awards 31,517 earned performance shares to R&D president - Stock Titan
Incyte (INCY) Expands AI Drug Discovery Partnership with Genesis Molecular AI - GuruFocus
Incyte gears up to report Q1 earnings: What can investors expect? - MSN
Q4 2025 Incyte Corp Earnings Call Transcript - GuruFocus
1.59%
0.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):